These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

124 related articles for article (PubMed ID: 2262963)

  • 21. [The correlation between the MICs deduced from Showa disk method and the MICs determined by micro-dilution method].
    Moroizumi S; Kasitani F; Isikawa M; Iwata M; Ohno A; Yamaguchi K
    Rinsho Byori; 1994 Oct; 42(10):1062-8. PubMed ID: 7996716
    [TBL] [Abstract][Full Text] [Related]  

  • 22. [Fundamental and clinical studies on aspoxicillin in the pediatric field].
    Iwai N; Taneda Y; Shibata M; Mizoguchi F; Nakamura H; Katayama M
    Jpn J Antibiot; 1985 Jul; 38(7):1868-81. PubMed ID: 3851860
    [TBL] [Abstract][Full Text] [Related]  

  • 23. [In vitro MIC break point for appropriate clinical use of antibiotic].
    Uete T; Matsuo K
    Jpn J Antibiot; 1993 Mar; 46(3):205-21. PubMed ID: 8510318
    [TBL] [Abstract][Full Text] [Related]  

  • 24. [Clinical laboratory approach for determination of effective dose of cefotiam. Observation from disc susceptibility test and MICs].
    Uete T; Tsuzaki Y; Furukawa S; Matsuo K
    Jpn J Antibiot; 1982 Jun; 35(6):1441-61. PubMed ID: 6290707
    [TBL] [Abstract][Full Text] [Related]  

  • 25. [Antibacterial activities of piperacillin for several resistant strains from respiratory infections--in reference to MRSA, PRSP, BLNAR and P. aeruginosa].
    Matsuzaki K; Koyama H; Omika K; Hasegawa M; Sato Y; Kobayashi I; Watanabe A
    Jpn J Antibiot; 2000 Aug; 53(8):566-72. PubMed ID: 11070818
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Determination of disc breakpoints and evaluation of Etests for tigecycline susceptibility testing by the BSAC method.
    Hope R; Parsons T; Mushtaq S; James D; Livermore DM
    J Antimicrob Chemother; 2007 Oct; 60(4):770-4. PubMed ID: 17704517
    [TBL] [Abstract][Full Text] [Related]  

  • 27. [Pharmacokinetic, bacteriological and clinical studies of SY5555 in the pediatric field].
    Motohiro T; Handa S; Yamada S; Oki S; Yoshinaga Y; Oda K; Sakata Y; Kato H; Yamashita F; Imai S
    Jpn J Antibiot; 1995 Feb; 48(2):238-60. PubMed ID: 7745814
    [TBL] [Abstract][Full Text] [Related]  

  • 28. [Multi-center evaluation of Showa disk susceptibility to presumptively determine minimum inhibitory concentrations through linear regression analysis].
    Sato Y; Nagata K; Tasaki Y; Tosaka M; Yamane N
    Rinsho Byori; 1991 Apr; 39(4):429-36. PubMed ID: 2051626
    [TBL] [Abstract][Full Text] [Related]  

  • 29. [A study on the disc sensitivity test for cefodizime].
    Kanazawa Y; Sekine H; Kuramata T; Saito H; Murata A; Ogino A
    Jpn J Antibiot; 1992 May; 45(5):459-67. PubMed ID: 1512931
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [Antibacterial activities of piperacillin in several fresh clinical isolates].
    Matsuzaki K; Koyama H; Omika K; Hasegawa M; Sato Y; Kobayashi I; Kaku M
    Jpn J Antibiot; 2000 Aug; 53(8):573-81. PubMed ID: 11070819
    [TBL] [Abstract][Full Text] [Related]  

  • 31. [Antibacterial activity of aztreonam against clinical isolates].
    Igari J
    Jpn J Antibiot; 1994 May; 47(5):502-20. PubMed ID: 8051793
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [A study of the disc sensitivity test for cefaclor].
    Kanazawa Y; Kuramata T; Matsumoto K
    Jpn J Antibiot; 1983 Apr; 36(4):717-24. PubMed ID: 6348334
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [A study on the disc sensitivity test for cefmenoxime].
    Kanazawa Y; Kuramata T; Matsumoto K
    Jpn J Antibiot; 1984 Jan; 37(1):176-83. PubMed ID: 6328060
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [A study on the disc sensitivity test for cefatrizine].
    Kanazawa Y; Kuramata T; Matsumoto K
    Jpn J Antibiot; 1983 Apr; 36(4):709-16. PubMed ID: 6348333
    [TBL] [Abstract][Full Text] [Related]  

  • 35. [Disc sensitivity test of cefuroxime].
    Kanazawa Y; Kuramata T; Matsumoto K
    Jpn J Antibiot; 1983 Jul; 36(7):1676-82. PubMed ID: 6655805
    [TBL] [Abstract][Full Text] [Related]  

  • 36. In vitro activity of teicoplanin and vancomycin against gram-positive bacteria from human clinical and veterinary sources.
    Jensen KT; Schønheyder H; Pers C; Thomsen VF
    APMIS; 1992 Jun; 100(6):543-52. PubMed ID: 1535201
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Development of a meropenem susceptibility disc: drug content, preliminary interpretive and quality control criteria and potency bioassay.
    Pitkin DH; Sheikh W; Nadler H
    J Antimicrob Chemother; 1989 Sep; 24 Suppl A():251-8. PubMed ID: 2808211
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Comparative in vitro activity of Meropenem, Imipenem and Piperacillin/tazobactam against 1071 clinical isolates using 2 different methods: a French multicentre study.
    Joly-Guillou ML; Kempf M; Cavallo JD; Chomarat M; Dubreuil L; Maugein J; Muller-Serieys C; Roussel-Delvallez M
    BMC Infect Dis; 2010 Mar; 10():72. PubMed ID: 20298555
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Reliability of routine disc susceptibility testing by the British Society for Antimicrobial Chemotherapy (BSAC) method.
    Potz NA; Mushtaq S; Johnson AP; Henwood CJ; Walker RA; Varey E; Warner M; James D; Livermore DM
    J Antimicrob Chemother; 2004 May; 53(5):729-38. PubMed ID: 15056636
    [TBL] [Abstract][Full Text] [Related]  

  • 40. [A study of the disc sensitivity test for cefotaxime].
    Kanazawa Y; Kuramata T; Matsumoto K
    Jpn J Antibiot; 1982 Jul; 35(7):1730-6. PubMed ID: 6294354
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.